What is the half-life of Methenolone Enanthate in Primabolin-100?

The terminal half-life of Methenolone Enanthate is approximately 10–14 days, as determined via GC-MS plasma pharmacokinetic studies. This extended half-life is attributable to the enanthate ester, which is hydrolysed slowly by tissue esterases at the intramuscular depot site. The result is a gradual, sustained release of free Methenolone into systemic circulation over roughly two weeks per injection.

How does the release profile of Methenolone Enanthate compare to Methenolone Propionate?

Methenolone Enanthate produces a significantly flatter concentration-time curve than Methenolone Propionate, which carries a half-life of only 2–3 days. The enanthate ester extends the release phase three to four times longer, eliminating the sharp plasma spikes associated with propionate. This makes Primabolin-100 better suited for protocols requiring stable hormone levels without daily or every-other-day injections.

What injection frequency is recommended based on Methenolone Enanthate's pharmacokinetics?

Based on the 10–14 day half-life, injecting Primabolin-100 once or twice per week — with administrations spaced 3–4 days apart — maintains plasma Methenolone within a stable steady-state range. Twice-weekly dosing is preferred by many users to minimise the peak-to-trough fluctuation, particularly when stacking with compounds that have shorter half-lives.

How should Primabolin-100 be stored after the 10ml vial is first opened?

Once punctured, Primabolin-100 should be stored upright at controlled room temperature (15–25°C), away from direct light and moisture. Oil-based multi-dose vials do not require refrigeration but must be protected from temperature extremes that could alter viscosity. The rubber stopper should be swabbed with 70% isopropyl alcohol before each draw, and the vial should be discarded per your local pharmaceutical waste guidelines after the stated use period.

Why is 100mg/ml considered an entry-level concentration and how does it affect dosing volumes?

At 100mg/ml — the lowest concentration available in Methenolone Enanthate injectables — a standard 400mg weekly dose requires only 4ml total, easily split across two 2ml injections. This volume is comfortably within the capacity of a standard 2.5ml or 3ml syringe, making Primabolin-100 accessible for users who prefer smaller gauge needles and reduced injection-site discomfort compared to higher-concentration formulations. (2) angle_used

Long-Acting Formula

BM Pharmaceuticals

Primabolin-100 100mg/ml 10ml Vial by BM Pharmaceuticals

Name: Primabolin-100 100mg/ml 10ml Vial by BM Pharmaceuticals
Brand: BM Pharmaceuticals
SKU: INJ-METE-BM-100-004
Price: 63.00 EUR
Availability: InStock

Primabolin-100 is an oil-based injectable anabolic agent delivering Methenolone Enanthate at 100mg/ml — a concentration engineered for predictable, sustained plasma release governed by the enanthate ester's extended pharmacokinetic profile. With an active half-life of approximately 10–14 days, blood concentrations remain stable between injections, eliminating the rapid oscillations characteristic of short-ester Methenolone preparations. Quality assurance is embedded at the batch level: every 10ml vial passes HPLC potency verification and LAL endotoxin testing within a GMP-certified production environment operated by BM Pharmaceuticals.

€63.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Sustained anabolic activity maintained across a 10–14 day release window per injection
Reduced injection burden — once-to-twice-weekly scheduling fits most training cycles
Flat plasma concentration curve minimises androgenic fluctuation between doses
100mg/ml concentration enables precise dose titration with standard syringe sizes
Nitrogen retention supported throughout the cycle without estrogenic conversion pathways
Multi-dose 10ml vial format reduces per-dose handling and cost over a full cycle
HPLC-confirmed label accuracy ensures each injection delivers the declared Methenolone payload

Phase	Weekly Dose	Injection Schedule (based on half-life)	Note
Introductory / Conservative	200–300mg	2 × per week (e.g., Mon/Thu)	Establishes steady-state plasma levels within 2–3 half-lives (~3–4 weeks); suitable for first-time Methenolone Enanthate users assessing individual response
Intermediate Lean-Mass	400–600mg	2 × per week, equal split	Optimal steady-state maintained by matching injection interval to ~0.5 × half-life; peak-to-trough ratio remains narrow at this frequency
Advanced / Pre-Contest	600–800mg	2 × per week, equal split	Higher plasma exposure requires extended post-cycle clearance; allow ≥2 half-lives (~3–4 weeks) before initiating PCT after the final injection

Key takeaways

Expect a 10–14 day active half-life from each Methenolone Enanthate injection.
Inject once or twice weekly to sustain stable plasma Methenolone concentrations.
Choose 100mg/ml for manageable injection volumes without concentration-related discomfort.
Verify potency batch-by-batch through HPLC documentation supplied by BM Pharmaceuticals.
Plan PCT timing around the enanthate ester's extended clearance window.

Methenolone Enanthate: A Compound Defined by Its Release Kinetics

Primabolin-100 delivers Methenolone Enanthate — an anabolic steroid whose biological behaviour is primarily determined by the enanthate ester's prolonged hydrolysis rate rather than the parent hormone alone. Once injected intramuscularly, esterases in muscle tissue cleave the enanthate chain gradually, releasing free Methenolone into systemic circulation over a period measured in days rather than hours. The terminal half-life of Methenolone Enanthate, established through pharmacokinetic studies using GC-MS plasma quantification, falls within the 10–14 day range — roughly three to four times longer than propionate-esterified Methenolone, which carries a half-life of approximately 2–3 days. This kinetic difference is clinically meaningful: users require injections only once or twice per week to maintain therapeutically relevant plasma concentrations.

Absorption, Distribution, and the Enanthate Release Curve

Following deep intramuscular administration, Primabolin-100 forms a depot at the injection site. The oily vehicle — acting as a diffusion-controlling matrix — slows the migration of the esterified compound into surrounding tissue capillaries. Methenolone Enanthate binds extensively to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG), which further modulates its free-fraction availability. Compared to aqueous suspensions of the same base compound, oil-based Methenolone Enanthate produces a flatter, more sustained concentration-time curve with a lower peak-to-trough ratio, reducing androgenic exposure spikes. The 100mg/ml concentration in Primabolin-100 allows precise volume management for weekly dosing protocols without requiring large injection volumes.

Dosing Frequency Derived From Half-Life Data

The pharmacokinetic half-life directly informs injection scheduling. At a 10–14 day half-life, two injections per week (spaced 3–4 days apart) maintain plasma Methenolone within a narrow, stable band — a pattern confirmed by steady-state modelling consistent with European Pharmacopoeia monograph principles. BM Pharmaceuticals formulates Primabolin-100 specifically to support this once-to-twice-weekly protocol, using a carrier oil optimised for depot formation and tolerability.

Analytical Verification and Manufacturing Standards

Every batch of Primabolin-100 undergoes HPLC quantification to confirm that active Methenolone Enanthate content corresponds to the declared 100mg/ml label claim, while LAL endotoxin assays ensure injectable-grade sterility. GMP certification governs all production stages, providing a documented quality chain from raw API sourcing through fill-and-finish.

Usage

Verify the vial label reads Methenolone Enanthate 100mg/ml and check the lot number against any available Certificate of Analysis before first use.
Warm the vial briefly in your hands or in a warm-water bath (max 35°C) if the oil has thickened — the enanthate carrier oil increases in viscosity at room temperatures below 18°C, slowing draw-up.
Swab the rubber stopper with 70% isopropyl alcohol and allow it to dry for 30 seconds before inserting the draw needle to maintain injectable-grade sterility.
Draw the calculated dose — e.g., 2ml for a 200mg injection at 100mg/ml — using an 18–21G needle for draw, then switch to a 23–25G needle for intramuscular injection to reduce tissue trauma.
Administer the injection slowly (1ml per 10 seconds) into the upper-outer gluteus, vastus lateralis, or deltoid; rotate sites systematically across the week's two injections to minimise depot accumulation discomfort.
Log each injection date and volume to track your pharmacokinetic timeline accurately — given the 10–14 day half-life, maintaining a schedule log ensures correct PCT start timing and prevents inadvertent dose stacking.

Warnings

Contraindications: Primabolin-100 is contraindicated in individuals with known hypersensitivity to Methenolone Enanthate or any excipient in the formulation, including the carrier oil. It must not be used in women who are pregnant or breastfeeding. Patients with existing hepatic impairment, prostate carcinoma, or androgen-sensitive tumours should avoid use entirely.

Side Effects: Androgenic effects — including accelerated scalp hair loss in genetically predisposed individuals, increased facial/body hair growth, and potential voice changes in females — may occur. Lipid profile alterations, specifically suppression of HDL cholesterol, have been documented with Methenolone use. Injection-site reactions (pain, induration, or localised inflammation) are possible, particularly with higher-volume administrations.

Monitoring: Serum lipid panels (HDL, LDL, total cholesterol) and haematocrit should be assessed at baseline and at 6-week intervals during prolonged cycles. Liver enzyme levels (ALT, AST) warrant periodic monitoring despite Methenolone's reputation for low hepatotoxicity. Endogenous testosterone suppression should be evaluated via LH, FSH, and total testosterone serum levels; given the 10–14 day half-life, HPTA suppression may persist for several weeks following the final injection.

PCT: Post-cycle therapy should be initiated approximately 2–3 weeks after the last Primabolin-100 injection — aligned with the enanthate ester's clearance timeline — using a standard SERM protocol (e.g., Nolvadex or Clomid) for 4–6 weeks to restore endogenous testosterone production.

Frequently asked questions

What is the half-life of Methenolone Enanthate in Primabolin-100?: The terminal half-life of Methenolone Enanthate is approximately 10–14 days, as determined via GC-MS plasma pharmacokinetic studies. This extended half-life is attributable to the enanthate ester, which is hydrolysed slowly by tissue esterases at the intramuscular depot site. The result is a gradual, sustained release of free Methenolone into systemic circulation over roughly two weeks per injection.
How does the release profile of Methenolone Enanthate compare to Methenolone Propionate?: Methenolone Enanthate produces a significantly flatter concentration-time curve than Methenolone Propionate, which carries a half-life of only 2–3 days. The enanthate ester extends the release phase three to four times longer, eliminating the sharp plasma spikes associated with propionate. This makes Primabolin-100 better suited for protocols requiring stable hormone levels without daily or every-other-day injections.
What injection frequency is recommended based on Methenolone Enanthate's pharmacokinetics?: Based on the 10–14 day half-life, injecting Primabolin-100 once or twice per week — with administrations spaced 3–4 days apart — maintains plasma Methenolone within a stable steady-state range. Twice-weekly dosing is preferred by many users to minimise the peak-to-trough fluctuation, particularly when stacking with compounds that have shorter half-lives.
How should Primabolin-100 be stored after the 10ml vial is first opened?: Once punctured, Primabolin-100 should be stored upright at controlled room temperature (15–25°C), away from direct light and moisture. Oil-based multi-dose vials do not require refrigeration but must be protected from temperature extremes that could alter viscosity. The rubber stopper should be swabbed with 70% isopropyl alcohol before each draw, and the vial should be discarded per your local pharmaceutical waste guidelines after the stated use period.
Why is 100mg/ml considered an entry-level concentration and how does it affect dosing volumes?: At 100mg/ml — the lowest concentration available in Methenolone Enanthate injectables — a standard 400mg weekly dose requires only 4ml total, easily split across two 2ml injections. This volume is comfortably within the capacity of a standard 2.5ml or 3ml syringe, making Primabolin-100 accessible for users who prefer smaller gauge needles and reduced injection-site discomfort compared to higher-concentration formulations. (2) angle_used

Manufacturer

BM Pharmaceuticals' quality framework for Primabolin-100 centres on validated analytical controls embedded at every critical stage of production rather than applied as a final release step. The facility's GMP certification — maintained under regulatory inspection schedules consistent with WHO Good Manufacturing Practice guidelines — mandates documented process controls for raw API qualification, in-process concentration checks, and terminal sterility assurance. ISO-classified clean-room manufacturing environments are used throughout fill-and-finish operations, with particulate and microbial monitoring data retained as batch records. For Primabolin-100 specifically, HPLC quantification of Methenolone Enanthate confirms label-claim accuracy at 100mg/ml, while LAL (Limulus Amebocyte Lysate) endotoxin assay results — validated against Ph. Eur. 2.6.14 acceptance criteria — accompany each production lot before any vial is released to distribution.

Product details

Brand	BM Pharmaceuticals
Active ingredient	methenolone enanthate
Also known as	Primobolan Depot, Primo, Methenolon Enanthat, Primabolin-100, BM Pharmaceuticals Primobolan Depot
Strength	100 mg
Form	Vial
Pack size	1 piece
Item number	INJ-METE-BM-100-004

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Primobol 100mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Primobol 100mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Primobol by Balkan Pharmaceuticals delivers Methenolone Enanthate at 100 mg/ml across ten glass-fusion sealed, single-dose ampoules — a format rooted in the original Schering AG clinical presentation that has defined this compound since its 1960s introduction for muscle-wasting indications. The 100 mg/ml concentration reflects the benchmark established during Methenolone's first decade of human clinical use, situating Primobol as a direct continuation of a molecule with more than sixty years of documented pharmacological history. Each ampoule is manufactured under GMP Annex 1 aseptic conditions at Balkan Pharmaceuticals' Chișinău facility; HPLC potency analysis and LAL endotoxin screening are completed at batch level before release.

€55.00

Rimobolan 100mg/ml 1x1ml Ampoules by Schering

GMP Standard

Rimobolan 100mg/ml 1x1ml Ampullen by Schering

Rimobolan by Bayer is a pharmaceutical-grade injectable anabolic agent delivering Methenolone Enanthate at 100 mg/ml in a single-use 1 ml glass ampoule, produced under EU Good Manufacturing Practice regulations governed by the European Medicines Agency (EMA) framework. Each batch undergoes rigorous release testing — including HPLC-based potency verification and LAL (Limulus Amebocyte Lysate) endotoxin screening — before leaving Bayer's licensed production site. Quality assurance is built into every stage: from raw-material qualification through in-process controls to final certificate of analysis.

€6.00

High Concentration

Etho-Primobolan 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Etho-Primobolan by Beligas Pharmaceuticals is a Methenolone Enanthate injectable at 100mg/ml in a 10ml multi-dose vial, engineered to integrate seamlessly into evidence-informed modern cycling strategies — whether as a base compound, a dry-tissue phase anchor, or a bridging agent between heavier blasts. Its long-acting ester supports once- or twice-weekly injection schedules that align with the structured periodisation models favoured by contemporary competitive and recreational athletes. Quality is verified across the full production chain: each batch undergoes HPLC potency assay and LAL endotoxin testing under Beligas's GMP-certified manufacturing framework.

€68.00

Brand Quality

PrimoTrex 150mg/ml 10ml Vial by Concentrex Labs

PrimoTrex by Concentrex Labs is a Methenolone Enanthate injectable formulated at 150 mg/ml in a 10 ml multi-dose vial, purpose-built for athletes who structure their training year around alternating high-output blast phases and lower-intensity cruise phases. The elevated 150 mg/ml concentration delivers meaningful dose flexibility within a single vial, reducing the number of injections required across both protocol phases. Quality release for each batch covers HPLC-verified potency and LAL endotoxin compliance; the finished vial clears distribution only after both assays confirm specification.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00